泊沙康唑缓释片在慢性肺曲霉病患者中的治疗药物监测与不良事件
200 mg与300 mg每日剂量均有90%患者达到治疗水平(≥1 mg/L),但300 mg组不良事件发生率更高(59% vs 39%,P<0.01)。女性、100 mg日剂量、哮喘和支气管扩张与亚治疗水平相关,300 mg剂量和哮喘与≥2级不良事件相关。
要点
- 200 mg每日剂量在多数患者中可达治疗水平且耐受性更好。
- 300 mg每日剂量与更高不良事件风险相关(P=0.001)。
- 女性、哮喘、支气管扩张及100 mg剂量与亚治疗水平相关。
核心结论
- 低于推荐剂量的泊沙康唑片在多数患者中达到治疗水平且耐受性更优。
- 男性更易达到治疗水平,基础疾病影响不良事件的程度和频率。
研究设计与样本
- 回顾性分析英国曼彻斯特国家曲霉病中心2014年2月至2015年10月启动泊沙康唑片治疗的慢性肺曲霉病患者。
主要发现
- 200 mg和300 mg每日剂量分别有90%病例达到治疗水平(≥1 mg/L),差异无统计学意义(P=not significant)。
- 300 mg/日时115/196次(59%)出现不良事件,200 mg/日时45/115次(39%)出现(P<0.01)。
- 无不良事件患者平均水平1.81±0.96 mg/L,有不良事件患者1.90±1.11 mg/L(P=not significant)。
- 多因素分析显示女性(P=0.041)、100 mg日剂量(P<0.001)、哮喘(P=0.01)和支气管扩张(P=0.001)与亚治疗水平相关;300 mg vs 200 mg日剂量(P=0.001)和哮喘(P=0.008)与≥2级不良事件相关。
临床怎么用
- 在慢性肺曲霉病患者中可考虑较低剂量泊沙康唑片以实现治疗水平并减少不良事件。
- 对女性、哮喘或支气管扩张患者应关注亚治疗水平风险,必要时进行治疗药物监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Posaconazole delayed-release tablets offer better bioavailability than the liquid suspension, but no post-marketing data are available in immunocompetent hosts such as those with chronic pulmonary aspergillosis (CPA). OBJECTIVES: To explore the pharmacokinetics and adverse event (AE) profile of posaconazole tablets in patients with CPA. METHODS: Patients started on posaconazole tablets at the National Aspergillosis Centre (NAC), Manchester, UK between February 2014 and October 2015 were identified from the NAC database and analysed retrospectively. The medical records were reviewed for factors that could affect posaconazole serum levels and the development of AEs. RESULTS: Seventy-two patients were included; 50 (69%) were male and the mean age was 48.5 ± 12 years. Therapeutic levels (≥1 mg/L) were achieved in 90% of cases on 200 mg versus 90% of cases on 300 mg daily (P = not significant). Based on multivariate analysis, female sex (P = 0.041), a 100 mg daily dose (P < 0.001), asthma (P = 0.01) and bronchiectasis (P = 0.001) were associated with subtherapeutic levels. Forty-nine (68%) patients developed AEs, mainly fatigue (37%), dyspnoea (18%) and nausea (12%). AEs were present on 115/196 (59%) occasions on 300 mg/day and on 45/115 (39%) occasions on 200 mg/day (P < 0.01). The mean level was 1.81 ± 0.96 mg/L for patients reporting no AEs and 1.90 ± 1.11 mg/L for those reporting AEs (P = not significant). Factors associated with AEs of grade ≥2 were a daily dose of 300 versus 200 mg (P = 0.001) and asthma (P = 0.008). CONCLUSIONS: A lower-than-recommended posaconazole tablet dose achieved therapeutic levels in most patients and was better tolerated. Males were more likely to achieve a therapeutic level. Underlying conditions affected the degree and frequency of AEs.
引用
- Kosmidis C, Rodriguez-Goncer I, Rautemaa-Richardson R, et al. Therapeutic drug monitoring and adverse events of delayed-release posaconazole tablets in patients with chronic pulmonary aspergillosis. J Antimicrob Chemother. 2019. PMID: 30590533. doi:10.1093/jac/dky539
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。